SGO Annual Meeting | Conference

Dr. Barber on Surgical Readmission and Survival in Ovarian Cancer

March 13th 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses surgical readmission and survival in patients with ovarian cancer.

Dr. Swisher on Next Steps of Treatment for Ovarian Cancer

March 13th 2017

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses next steps regarding treatments for patients with ovarian cancer.

New Insights Into Rucaparib Activity in Ovarian Cancer

March 13th 2017

The PARP inhibitor rucaparib slowed progression of relapsed BRCA-mutant ovarian cancer regardless of whether the mutations were somatic or germline, a new analysis of a phase II trial showed.

Ovarian Cancer Study Fails to Settle Debate Over Chemotherapy Regimens

April 22nd 2016

Intraperitoneal therapy was not superior to intravenous treatment when used in combination with bevacizumab (Avastin) as a regimen for patients with advanced ovarian cancer.

Targeted Drug Falls Short Versus Paclitaxel for Ovarian Cancer

March 22nd 2016

Weekly paclitaxel for recurrent ovarian cancer prevailed over the VEGF inhibitor cabozantinib in a randomized comparison of the two drugs.

Trial of Ovarian Chemotherapy Regimens Fails to Provide Clarity

March 22nd 2016

Three different chemotherapy regimens, each combined with bevacizumab, failed to demonstrate an advantage for patients with advanced ovarian cancer or build on results of a landmark trial reported more than a decade ago.

Phase III Studies Aim to Expand Olaparib's Ovarian Cancer Approval

March 22nd 2016

Ursula A. Matulonis, MD, discusses ongoing developments with olaparib, as well as the overall future of PARP inhibitors in ovarian cancer.

Dr. Jean Hurteau on Diagnosing Ovarian Clear Cell Carcinoma

March 21st 2016

Jean Hurteau, MD, professor, Division of Gynecologic Oncology at NorthShore University Health System, discusses the difficulties of diagnosing ovarian clear cell carcinoma. Hurteau says data for the diagnosis of the carcinoma is older, and is not relevant to contemporary diagnoses due to the fact that there were more mixed tumors previously than there are now.

Dr. Bobbie J. Rimel on Genetic Testing in Ovarian Cancer

March 21st 2016

Bobbie J. Rimel, MD, assistant professor, Obstetrics and Gynecology, discusses discovering BRCA mutations early in ovarian cancer patients. Rimel says with the genetic information of knowing which patients harbor which genetic mutations, oncologists can offer their patients treatments such as PARP inhibitors, which are gene-specific.

Trial Tests Combo of Pexidartinib and Pembrolizumab in Ovarian and Other Solid Tumors

March 21st 2016

An ongoing clinical trial has begun the process of evaluating whether the addition of a booster agent can take the anticancer activity of PD-1 directed immunotherapy to another level.

Researchers Seek to Optimize PARP Inhibitors in Ovarian Cancer

March 21st 2016

Shannon Westin, MD, discusses refining the use of PARP inhibitors in ovarian cancer by gaining a greater understanding of mechanisms of resistance and exploring combination and sequencing possibilities.

New Antiemetic Compares Favorably With Standard for Cisplatin Regimens

March 21st 2016

An investigational extended-release formulation of the antiemetic granisetron achieved a complete response more often than did ondansetron in cancer patients receiving highly emetogenic cisplatin-based chemotherapy.

Dr. Terri Febbraro on the Inverse Correlation Between Time on Chemotherapy and OS

March 21st 2016

Terri Febbraro, MD, third year fellow, University of Chicago/NorthShore University Health System, discusses length of time receiving chemotherapy versus overall survival in patients with ovarian cancer. Febbraro says the study looked at three separate groups of patients with ovarian cancer based on the length of time they receieved chemotherapy, with the group being on chemotherapy the longest having the worst overall survival rates.

Dr. Martee Hensley on Trabectedin as a Treatment for Uterine Leiomyosarcoma

March 21st 2016

Martee Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the introduction of trabectedin into the armamentarium for uterine leiomyosarcoma. Hensley says the FDA approval for the treatment requires patients to have had a prior anthracycline therapy, and the treatment will likely fall into the third- or fourth-line of treatment for the malignancy. She adds that trabectedin may fall into the fourth-line due to treatments such as pazopanib currently occupying the third-line.

Trabectedin Significantly Slows Progression in Uterine Leiomyosarcoma

March 20th 2016

Treatment with trabectedin significantly improved progression-free survival compared with dacarbazine in women with advanced uterine leiomyosarcoma, according to a subgroup analysis of the phase III SAR-3007 trial.

Dr. Emily Ko on the Role of Surgery in Endometrial Cancer

March 20th 2016

Emily Ko, MD, assistant professor of Obstetrics and Gynecology, University of Pennsylvania Health System, discusses the role of surgery in endometrial cancer and the candidacy of patients for the procedure.

Combined Biomarker Score Is Better Survival Predictor in Ovarian Cancer

March 20th 2016

Combining 3 markers of homologous recombination deficiency significantly improved prediction of outcome of platinum-based treatment of ovarian cancer compared with the individual markers, a retrospective analysis of tissue samples showed.

Dr. Terri Woodard on Preservative Measures for Women With Ovarian Cancer

March 20th 2016

Terri Woodard, MD, assistant professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses if conservative management for women with ovarian cancer is warranted.

BRCA Mutations Linked to Longer Survival in Ovarian Cancer

March 19th 2016

Patients with advanced ovarian cancer harboring mutations in homologous recombination (HR) genes, including BRCA1/2, had improved survival outcomes versus patients without HR mutations.

Dr. Markman on the Future of Treatment for Ovarian Cancer

April 13th 2015

Maurie Markman, MD, national director, Cancer Treatment Centers of America, discusses what he sees as future treatment paradigms in ovarian cancer.